Trial Profile
A Phase 2 study evaluating the efficacy and safety of topical diacerein 1% compared with placebo in patients with Epidermolysis Bullosa Simplex (EBS).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2018
Price :
$35
*
At a glance
- Drugs Diacerein (Primary)
- Indications Epidermolysis bullosa
- Focus Therapeutic Use
- 09 Aug 2018 Results presented in a Castle Creek Pharmaceuticals media release.
- 06 Mar 2017 According to a Castle Creek Pharmaceuticals media release, results from the study have been presented in a late-breaker session at the American Academy of Dermatology Annual Meeting.
- 06 Mar 2017 Results published in a Castle Creek Pharmaceuticals media release.